Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q2 FY2022 Earnings Presentation
12 slides from Gland Pharma's earnings presentation, Oct 22, 2021
Slide 1: Gland Pharma Limited Financial Results Q2 FY22
Gland Pharma Limited Financial Results Q2’FY22 22nd October 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Financial Highlights (1/3)
Financial Highlights (1/3) Healthy growth in profitability while focus on R&D continues Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) 9,259 22,344 7,628 10,805 4,278 17,157 8,315 3,181 39% 37% 38% 43% Q2 FY21 Q2 FY22 6M FY21 6M FY22 Q2 FY21 Q2 FY22 6M FY21 6M FY22 PBT
Slide 4: Financial Highlights (2/3)
Financial Highlights (2/3) Balance sheet continues to remain strong while CapEx remains in line with growth plans Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 65,956 59,032 12,250 12,250 30,058 30,017 29,822 29,782 53,706 46,782 Mar'21 Sep'21 Mar'21 Sep'21 Networth Fresh iss
Slide 5: Financial Highlights (3/3)
Financial Highlights (3/3) Focus on Capital efficiency and healthy return ratios Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.4 3.0 2.8 39% 35% 35% 27% 21% 21% 27% 0.8 0.7 0.7 21% 21% (8) (8) Total asset turnover Fixed asset turnover 6M FY21 FY21 6M FY22 6M FY21 FY21 6M
Slide 6: P&L Highlights
P&L Highlights (INR Mn) YoY YoY Amount in INR Mn Q2 FY22 Q2 FY21 6M FY22 6M FY21 Q1 FY22 growth growth Revenue From operations 10,805 8,315 30% 22,344 17,157 30% 11,539 Other Income 512 204 152% 1,130 524 116% 618 Total income 11,317 8,519 33% 23,474 17,681 33% 12,157 Gross Margin(1) 5,565 4,580 21%
Slide 7: USA, Europe, Canada and Australia (Core Markets)
USA, Europe, Canada and Australia (Core Markets) Revenue: 6M FY22: Rs. 13,689 Mn Q2 FY22: Rs. 6,648 Mn YoY Growth: 20% (21%) YoY Growth: 25% (27%) With declining COVID-19 hospitalizations, we observed a (%) - including India sales for our core markets shift in product mix. Our wide therapeutic por
Slide 8: Rest of the World Markets
Rest of the World Markets Rest of the world markets continue to grow faster than 6M FY22: Rs. 4,549 Mn Q2 FY22: Rs. 2,322 Mn YoY Growth: 55% YoY Growth: 59% other geographies, with strong demand from countries including Brazil, Saudi Arabia, Thailand among others. Rest of the World Markets Stron
Slide 9: India (Domestic Market)
India (Domestic Market) India sales grew by 19% on account of volume growth 6M FY22: Rs. 4,106 Mn Q2 FY22: Rs. 1,835 Mn YoY Growth: 45% YoY Growth: 19% of existing products like Enoxaparin Sodium and Heparin Sodium Injection India (Domestic Market) The new capacities being made available for the
Slide 10: Focus on expanding capabilities in Complex Injectables
Focus on expanding capabilities in Complex Injectables We are working towards building complex manufacturing and development capabilities Focussed on development of Complex Injectables: Expanding capabilities in: Completed planned submission batches for complex Peptides injectables to be filed i
Slide 11: Entry into Biologics CDMO Market
Entry into Biologics CDMO Market We are exploring partnerships to accelerate entry into the Biologics CDMO market Biologics market is currently about USD 300 Bn in size, within which the biologics CDMO market is estimated at nearly USD 13 Bn, Biologics Market Size CDMO Market size (USD Bn) (USD Bn
Slide 12: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder